vs

Side-by-side financial comparison of Elme Communities (ELME) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

Elme Communities is the larger business by last-quarter revenue ($62.1M vs $35.5M, roughly 1.7× RECURSION PHARMACEUTICALS, INC.). Elme Communities runs the higher net margin — -198.9% vs -304.2%, a 105.4% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 1.7%). Elme Communities produced more free cash flow last quarter ($7.2M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 2.7%).

Elme Communities is a publicly traded U.S. real estate investment trust that primarily owns, operates and develops high-quality multifamily residential communities. It focuses on key growth markets across the U.S. Mid-Atlantic and Southeast, offering affordable to mid-tier housing options for diverse renter groups.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

ELME vs RXRX — Head-to-Head

Bigger by revenue
ELME
ELME
1.7× larger
ELME
$62.1M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+680.0% gap
RXRX
681.7%
1.7%
ELME
Higher net margin
ELME
ELME
105.4% more per $
ELME
-198.9%
-304.2%
RXRX
More free cash flow
ELME
ELME
$54.5M more FCF
ELME
$7.2M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
2.7%
ELME

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ELME
ELME
RXRX
RXRX
Revenue
$62.1M
$35.5M
Net Profit
$-123.5M
$-108.1M
Gross Margin
61.1%
59.8%
Operating Margin
-183.3%
-304.8%
Net Margin
-198.9%
-304.2%
Revenue YoY
1.7%
681.7%
Net Profit YoY
-4058.7%
39.6%
EPS (diluted)
$-1.40
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ELME
ELME
RXRX
RXRX
Q4 25
$35.5M
Q3 25
$62.1M
$5.2M
Q2 25
$62.1M
$19.2M
Q1 25
$61.5M
$14.7M
Q4 24
$61.3M
$4.5M
Q3 24
$61.1M
$26.1M
Q2 24
$60.1M
$14.4M
Q1 24
$59.5M
$13.8M
Net Profit
ELME
ELME
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$-123.5M
$-162.3M
Q2 25
$-3.6M
$-171.9M
Q1 25
$-4.7M
$-202.5M
Q4 24
$-3.0M
$-178.9M
Q3 24
$-3.0M
$-95.8M
Q2 24
$-3.5M
$-97.5M
Q1 24
$-3.6M
$-91.4M
Gross Margin
ELME
ELME
RXRX
RXRX
Q4 25
59.8%
Q3 25
61.1%
-183.8%
Q2 25
63.5%
-4.9%
Q1 25
64.2%
-48.0%
Q4 24
62.9%
-181.4%
Q3 24
63.5%
53.7%
Q2 24
63.4%
36.2%
Q1 24
63.5%
19.1%
Operating Margin
ELME
ELME
RXRX
RXRX
Q4 25
-304.8%
Q3 25
-183.3%
-3327.6%
Q2 25
9.6%
-916.8%
Q1 25
7.8%
-1297.9%
Q4 24
10.4%
-4042.4%
Q3 24
11.0%
-377.1%
Q2 24
9.8%
-697.4%
Q1 24
7.5%
-698.4%
Net Margin
ELME
ELME
RXRX
RXRX
Q4 25
-304.2%
Q3 25
-198.9%
-3135.3%
Q2 25
-5.7%
-894.2%
Q1 25
-7.6%
-1373.3%
Q4 24
-4.9%
-3935.5%
Q3 24
-4.9%
-367.5%
Q2 24
-5.8%
-676.6%
Q1 24
-6.1%
-662.4%
EPS (diluted)
ELME
ELME
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$-1.40
$-0.36
Q2 25
$-0.04
$-0.41
Q1 25
$-0.05
$-0.50
Q4 24
$-0.04
$-0.56
Q3 24
$-0.03
$-0.34
Q2 24
$-0.04
$-0.40
Q1 24
$-0.04
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ELME
ELME
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$7.1M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$908.9M
$1.1B
Total Assets
$1.7B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ELME
ELME
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$7.1M
$659.8M
Q2 25
$4.8M
$525.1M
Q1 25
$6.4M
$500.5M
Q4 24
$6.1M
$594.4M
Q3 24
$4.8M
$427.6M
Q2 24
$5.6M
$474.3M
Q1 24
$4.2M
$296.3M
Total Debt
ELME
ELME
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
ELME
ELME
RXRX
RXRX
Q4 25
$1.1B
Q3 25
$908.9M
$1.0B
Q2 25
$1.0B
$919.1M
Q1 25
$1.1B
$933.9M
Q4 24
$1.1B
$1.0B
Q3 24
$1.1B
$524.6M
Q2 24
$1.1B
$584.4M
Q1 24
$1.1B
$401.2M
Total Assets
ELME
ELME
RXRX
RXRX
Q4 25
$1.5B
Q3 25
$1.7B
$1.4B
Q2 25
$1.8B
$1.3B
Q1 25
$1.8B
$1.3B
Q4 24
$1.8B
$1.4B
Q3 24
$1.9B
$726.5M
Q2 24
$1.9B
$775.9M
Q1 24
$1.9B
$557.8M
Debt / Equity
ELME
ELME
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ELME
ELME
RXRX
RXRX
Operating Cash FlowLast quarter
$15.9M
$-46.1M
Free Cash FlowOCF − Capex
$7.2M
$-47.3M
FCF MarginFCF / Revenue
11.6%
-133.1%
Capex IntensityCapex / Revenue
14.0%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$86.7M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ELME
ELME
RXRX
RXRX
Q4 25
$-46.1M
Q3 25
$15.9M
$-117.4M
Q2 25
$29.8M
$-76.4M
Q1 25
$16.2M
$-132.0M
Q4 24
$95.2M
$-115.4M
Q3 24
$20.7M
$-59.2M
Q2 24
$28.9M
$-82.2M
Q1 24
$21.2M
$-102.3M
Free Cash Flow
ELME
ELME
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$7.2M
$-117.6M
Q2 25
$21.1M
$-79.6M
Q1 25
$10.5M
$-133.8M
Q4 24
$47.9M
$-116.7M
Q3 24
$8.8M
$-63.8M
Q2 24
$21.0M
$-83.4M
Q1 24
$7.6M
$-109.0M
FCF Margin
ELME
ELME
RXRX
RXRX
Q4 25
-133.1%
Q3 25
11.6%
-2272.5%
Q2 25
34.1%
-413.9%
Q1 25
17.1%
-907.4%
Q4 24
78.1%
-2567.7%
Q3 24
14.4%
-244.6%
Q2 24
34.9%
-578.5%
Q1 24
12.8%
-789.9%
Capex Intensity
ELME
ELME
RXRX
RXRX
Q4 25
3.5%
Q3 25
14.0%
4.7%
Q2 25
14.0%
16.4%
Q1 25
9.2%
12.4%
Q4 24
77.4%
28.6%
Q3 24
19.4%
17.5%
Q2 24
13.1%
8.2%
Q1 24
22.9%
48.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ELME
ELME

Residential Segment$57.7M93%
Other$4.4M7%

RXRX
RXRX

Segment breakdown not available.

Related Comparisons